Kiran Mazumdar-Shaw, Rohini Nilekani, Kris Gopalakrishnan jointly pledge Rs 51 crore to Science Gallery Bengaluru Press Trust of India University of Glasgow names new research centre after Kiran ...

Learn how to enhance your leadership skills from EY World Entrepreneur of the Year 2020 Kiran Mazumdar-Shaw who has succeeded in managing, influencing, and inspiring the business world for nearly ...

On June 5, Biocon’s Executive Chairperson Kiran Mazumdar Shaw was named as EY World Entrepreneur of the Year 2020. With this, she joined Uday Kotak of Kotak Mahindra Bank and Narayana Murthy of ...

Kiran Mazumdar-Shaw is the executive chairperson of Biocon, a major Indian producer of pharmaceutical ingredients, generics, and biosimilars. Mazumdar-Shaw founded the company in 1978 in the ...

US-India Business Council (USIBC) has selected Biocon Executive Chairperson Kiran Mazumdar-Shaw as one of its vice-chairs effective immediately. US Chamber of Commerce's USIBC on January 14 ...

Kiran Mazumdar-Shaw, the founder of pharmaceutical giant Biocon, has also expressed her opinion on the issue. Shaw has opposed a reservation in highly skilled recruitment from this policy and also ...

New Delhi, Nov 21 () Kiran Mazumdar Shaw, lead independent director of Infosys, has settled with Sebi a case of alleged delay in making disclosure regarding change in her shareholding in the IT ...

The startup, co-founded by Kiran Mazumdar-Shaw, was the first company in India ... this is still prohibitive for a majority of Indians. “It's too early [to tell] whether Indian patients or ...

Kiran Mazumdar-Shaw (@kiranshaw) February 1, 2025 Consumption, investment, innovation & employment are the 4 pillars of our economic growth model and FM @nsitharaman has focused on all aspects of ...

Biocon's Kiran Mazumdar-Shaw posted on social media platform X (formerly known as Twitter), wishing fellow Indians a happy republic day. “Every Republic Day we celebrate the pride of being a ...

Biocon Executive Chairperson Kiran Mazumdar Shaw says scarcity of critical anti-COVID-19 drugs Remdesivir and Itolizumab will end in 4-6 weeks as suppliers like her own company ramp up output that ...